Mediterranean Diet

The Mediterranean diet, olive oil, vegetables, legumes, fish, moderate wine, limited red meat, has the largest single trial base of any diet pattern studied for cardiovascular and mortality outcomes. Its flagship trial is PREDIMED, a Spanish multi-center RCT of 7,447 adults at high cardiovascular risk, randomized to Mediterranean diet plus extra-virgin olive oil, Mediterranean diet plus nuts, or a low-fat control diet.

PREDIMED was stopped early, at a median 4.8 years of a planned 6, after an interim analysis showed the olive-oil arm cut the composite cardiovascular endpoint (heart attack, stroke, cardiovascular death) by roughly 30% relative risk, and the nuts arm by roughly 28%, both against the control diet [1]. Sofi and colleagues' meta-analyses pooling PREDIMED alongside dozens of cohort studies found a consistent dose-response relationship: each two-point increase on a Mediterranean diet adherence score tracks with lower all-cause mortality across a wide range of populations [2][3].

What the evidence does not show, and this is a real methodological limitation rather than a minor footnote, is that PREDIMED measured all-cause mortality as its primary success. Its primary endpoint was the composite cardiovascular event outcome, not death from any cause. A widely cited critique published in the same journal ecosystem points out that PREDIMED's early stopping, combined with an imbalance in how intensively the diet arms versus control arm were counseled, complicates interpretation of the trial's effect size [4]. A 2021 MDPI Nutrients meta-analysis in cardiovascular-disease patients found a more modest, borderline-significant pooled hazard ratio of 0.91 per two-unit increase in Mediterranean diet score (95% CI 0.82-1.01), with substantial heterogeneity across included studies (I-squared 88.9%) [5]. The effect is real but its exact size is less settled than the PREDIMED headline number alone suggests.

Who this does not work for, or where the evidence is weakest: PREDIMED enrolled adults already at high cardiovascular risk, so the trial's 30% relative-risk-reduction figure describes secondary-prevention-like benefit in a high-risk population, not necessarily what a healthy 35-year-old should expect from switching diets. People with nut allergies cannot use the nuts-supplemented arm of the diet. The counseling-intensity imbalance between PREDIMED's diet arms and its control arm means part of the measured benefit could reflect more attention and support, not diet composition alone, a criticism that applies to many free-living dietary RCTs but is specifically documented for PREDIMED [4]. And because the primary endpoint was cardiovascular events, claims that the Mediterranean diet reduces all-cause mortality rest more heavily on the cohort literature than on PREDIMED itself.

The diet's plausibility as a longevity intervention rests on a combination of anti-inflammatory fatty-acid profile (olive oil's monounsaturated fat, fish omega-3s), high polyphenol and fiber content, and displacement of processed food and red meat, all mechanisms independently linked to lower cardiometabolic risk. It is also the dietary backbone borrowed by several self-experimenters, including Bryan Johnson's Blueprint protocol, which uses PREDIMED's olive-oil arm as its primary cited justification for daily olive oil intake.

Plain takeaway: the Mediterranean diet has the strongest trial evidence of any whole-diet pattern for reducing cardiovascular events in people already at elevated risk, roughly 30% relative risk reduction in PREDIMED, with consistent supporting cohort data on all-cause mortality, but the flagship trial's early stopping and counseling imbalance mean the exact effect size for a healthy, low-risk population is less certain than the topline number implies.